Brazil Turns to Italian Region for Pioneering Neonatal Genomic Screening Programme
Table of Contents
Puglia’s Genoma-puglia program has been lauded as an international model for accessible and innovative genomic healthcare, prompting a formal collaboration request from Brazil’s leading public health institution.
In a landmark development for global healthcare, Brazil has officially sought to collaborate with the Italian region of Puglia on its groundbreaking neonatal genomic screening program, genoma-Puglia. The request, formalized in a letter from the Fundação Oswaldo Cruz (Fiocruz), the largest scientific and public health institution in Latin America, recognizes Puglia’s program as a “global reference point” and an “international benchmark” in the field.
The collaboration aims to replicate the success of Genoma-Puglia within the Brazilian healthcare system,specifically through its two national programs – Genomas SUS,promoted by the Brazilian Ministry of Health,and Napi-Spp,operating in the State of Paraná. Both Brazilian initiatives are focused on integrating genomic sequencing into the clinical pathways of newborns and critically ill patients.
“It is indeed not every day that we observe a country of around 214 million inhabitants like Brazil, which identifies a region of around 4 million inhabitants like Puglia as a possible partner,” stated a regional official, highlighting the significance of the partnership. The initiative signifies a shift towards proactive, preventative healthcare on a national scale.
A Lifesaving Program Takes Root
The Genoma-Puglia program, born from regional legislation, currently provides genomic sequencing for a panel of 407 genes for all newborns in the region. This extensive screening allows for the diagnosis or identification of over 480 diseases treatable with early interventions. The test, conducted via a simple blood sample in the frist days of life, activates critical clinical and therapeutic pathways, potentially altering the course of a child’s life.
As its launch as a structural activity in April 2025-a remarkably swift implementation-the program has analyzed over 16,000 children – including those from a prior experimental phase between June and November 2024 – leading to early diagnoses and treatment for dozens of pathogenic conditions. The program also provides valuable genetic counseling for families.
Fiocruz: A Legacy of Public Health Innovation
The impetus for collaboration stems from Fiocruz’s deep respect for Puglia’s achievements. Founded in 1900 as the Serum Therapeutic Institute, Fiocruz has a storied history of combating infectious diseases, including leading campaigns against plague, yellow fever, and smallpox. The institution also played a pivotal role in isolating HIV for the first time in Latin America in the 1980s and, more recently, decoding the genome of the BCG bacterium used in the tuberculosis vaccine.
“Our work represents a global reference point for innovation, accessibility and integration of genomics in public health,” noted the director of Fiocruz’s Center for Precision Public Health, Fabio Passetti, in the formal request. This recognition underscores the program’s potential to serve as a model for other nations.
A Call for Global standards
The proposed collaboration isn’t limited to a simple exchange of facts. The partnership aims to establish a “structural and guaranteed service” for all newborns, mirroring Puglia’s approach, and potentially paving the way for national standards and equitable access to genomic screening across both countries.
“It is confirmation that the path is right: saving children from illness and death as soon as possible, without wasting time with bureaucratic hesitations or power struggles,” explained a senior official involved in the program. The sentiment reflects a growing global consensus on the importance of early diagnosis and intervention in improving health outcomes.
The collaboration also represents a broader opportunity to consolidate an international alliance, boost scientific production, and position Italy – through Puglia – as a leader in defining global genomic screening protocols. As one analyst observed,”while discussions about the feasibility of these innovations continue in some regions,the rest of the world is actively seeking collaboration.”
